1–2 ml EDTA blood or 1–2 µg genomic DNA. Alternative material must be confirmed before collection or shipment.
PREVENTION · PRV08
Drug Metabolization / Pharmacogenetics
Assesses pharmacogenetic variants in drug-metabolism, transport, immune-risk, and adverse-reaction genes interpreted against recognized prescribing guidance.
Targeted pharmacogenetic analysis of relevant variants in 21 genes, interpreted using current CPIC and DPWG guidance where applicable.
Gene–drug findings and prescribing implications for covered medications; the treating clinician remains responsible for the final prescription.
Confirmed after sample review.
CLINICAL VALUE
Where this test is strongest
✓21 pharmacogenes
✓More than 100 medicines in the referenced scope
✓Includes metabolism, transport, HLA risk, and anesthesia genes
✓Can be reused when covered medicines are considered
LIMITATIONS
What must remain visible
!Only covered genes, alleles, and medicines are assessed.
!Do not start, stop, or change a medicine without the prescribing clinician.
!The current validation and applicable accreditation scope must be confirmed in the quotation.
GENE & ANALYTICAL SCOPE
21 published genes
Relevant variant analysis in 21 pharmacogenes; not every variant in every gene is clinically reportable.
Drug metabolizationPRV08 · 21 published genes+
Complete pharmacogene scope (21 genes).
ABCG2CACNA1SCYP2B6CYP2C19CYP2C9CYP2D6CYP3A4CYP3A5CYP4F2DPYDG6PDHLA-AHLA-BIFNL4MT-RNR1NUDT15RYR1SLCO1B1TPMTUGT1A1VKORC1
BEFORE ORDERING
Confirm the current laboratory specification.
The official case review and quotation confirm eligibility, accepted material, validated coverage and variant classes, consent, turnaround, price, and report pathway.